ALEC Share Price Performance
US$0
-1.41 (-100.00%)
Price US$0
Fair ValueUS$3.10
Share Pricen/a
Narrative Update • Jun 03
Alector, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ALEC Community Narratives
AN
Fair Value
·Fair Value US$3.1 47.3% undervalued intrinsic discount
Analysts Cut Alector Price Target as Latozinemab Failure Drives Valuation Shift
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$1 63.5% overvalued intrinsic discount
Overvaluation Will Deflate Prospects In A Niche Neurology Market
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$6 72.8% undervalued intrinsic discount
Global Aging And Genomics Will Unlock Neurodegeneration Breakthroughs
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Global Aging And Genomics Will Unlock Neurodegeneration Breakthroughs
Alector is betting on new medicines for brain diseases, with upcoming trial results and close work with regulators that could speed the path to approval and widen who can use its treatments. The upside comes with big risks, though: if a key late-stage study disappoints or payers push back on coverage, growth could stall and the company may need to raise more money.Read more
AN
US$6
72.8% undervalued intrinsic discount
Fair Value
Profit Margin
19.04%
Future PE
1.31kx
Price in 2029
US$7.43
Analysts Cut Alector Price Target as Latozinemab Failure Drives Valuation Shift
Alector’s stock hinges on a make-or-break late-stage readout for a drug aimed at a rare, fatal brain disease, after a setback forced analysts to rethink what the business could be worth. The company also has a platform and big-partner ties that could open doors in larger brain disorders, but the path depends on trial wins, funding needs, and tough competition.Read more
AN
US$3.1
47.3% undervalued intrinsic discount
Fair Value
Profit Margin
18.87%
Future PE
2.12kx
Price in 2029
US$3.83
Overvaluation Will Deflate Prospects In A Niche Neurology Market
Key Takeaways Alector's limited target market and intense pricing pressures threaten future revenue growth and profit potential, even with successful regulatory outcomes. Persistent financial losses and competition from larger biotech firms increase risks of dilution, delays, and challenges in attracting resources and partnerships.Read more
AN
US$1
63.5% overvalued intrinsic discount
Fair Value
Profit Margin
14.17%
Future PE
65.76x
Price in 2028
US$1.21
Trending Discussion
Recently Updated Narratives
AN
ALEC: BBB Shuttle Pivot And Tau Readthrough Will Reset Neurodegeneration Prospects
Fair Value: US$6 72.8% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ALEC: Tau Readthroughs And BBB Shuttle Platform Will Drive Neurodegeneration Upside
Fair Value: US$3.1 47.3% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Overvaluation Will Deflate Prospects In A Niche Neurology Market
Fair Value: US$1 63.5% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alector, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -1.13
- -482.51%
- -680.83%
- 94.1%
About ALEC
- Founded
- 2013
- Employees
- 103
- CEO
- WebsiteView website
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Recent ALEC News & Updates
Narrative Update • May 17
